| P50 | author | Xiaosheng Wang | Q82275863 |
| P2093 | author name string | Richard Simon | |
| P2860 | cites work | Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy | Q21245716 |
| | DRAKs, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis | Q22003997 |
| | Cyclin-dependent kinase 16/PCTAIRE kinase 1 is activated by cyclin Y and is essential for spermatogenesis | Q24300150 |
| | Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation | Q24301892 |
| | A human homolog of the yeast Ssk2/Ssk22 MAP kinase kinase kinases, MTK1, mediates stress-induced activation of the p38 and JNK pathways | Q24313172 |
| | A serine kinase regulates intracellular localization of splicing factors in the cell cycle | Q24317050 |
| | Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment | Q24317541 |
| | Targeting the protein kinase C family: are we there yet? | Q52579980 |
| | Restoration of the transcription activation function to mutant p53 in human cancer cells | Q71865200 |
| | The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1 | Q79754843 |
| | Plk4-induced centriole biogenesis in human cells | Q24336451 |
| | Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease | Q24531988 |
| | Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma | Q24619532 |
| | Regulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cells | Q24646815 |
| | A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene | Q24647664 |
| | A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 | Q24657532 |
| | Targeting the mTOR signaling network for cancer therapy | Q24658334 |
| | Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells | Q24675189 |
| | Automated screening of microtubule growth dynamics identifies MARK2 as a regulator of leading edge microtubules downstream of Rac1 in migrating cells | Q27332112 |
| | Functions of mammalian Cdc7 kinase in initiation/monitoring of DNA replication and development | Q28187866 |
| | Raf kinases in cancer-roles and therapeutic opportunities | Q28237793 |
| | Protein kinase C (PKC) family in cancer progression | Q28252013 |
| | Aurora A, meiosis and mitosis | Q28265407 |
| | The concept of synthetic lethality in the context of anticancer therapy | Q28268061 |
| | Upstream and downstream of mTOR | Q28277365 |
| | Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells | Q28286189 |
| | Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features | Q28301684 |
| | p53 mutations in human cancers | Q28302973 |
| | Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes | Q28307762 |
| | Polo-like kinases and the orchestration of cell division | Q29616759 |
| | Restoration of p53 function leads to tumour regression in vivo | Q29618727 |
| | Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. | Q30831001 |
| | Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. | Q31041084 |
| | Gene expression patterns associated with p53 status in breast cancer. | Q33265626 |
| | Methodological approaches in application of synthetic lethality screening towards anticancer therapy | Q33421697 |
| | Analysis of gene expression data using BRB-ArrayTools. | Q33448521 |
| | CellMiner: a relational database and query tool for the NCI-60 cancer cell lines | Q33472990 |
| | Aurora kinase inhibitors--rising stars in cancer therapeutics? | Q33647643 |
| | The coordinate regulation of the p53 and mTOR pathways in cells | Q33840457 |
| | The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein. | Q33914706 |
| | A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly | Q33923357 |
| | Control of the eukaryotic cell cycle by MAP kinase signaling pathways. | Q34071364 |
| | Kinetic properties of p53 phosphorylation by the human vaccinia-related kinase 1. | Q34117431 |
| | Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers | Q34162501 |
| | Mindbomb 1, an E3 ubiquitin ligase, forms a complex with RYK to activate Wnt/β-catenin signaling | Q34211643 |
| | Targeting mTOR signaling for cancer therapy | Q34220084 |
| | p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma | Q34547830 |
| | p53-dependent apoptosis in response to spindle damage is linked to loss of Bub1. | Q34958908 |
| | Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer | Q35600870 |
| | The functional interactions between the p53 and MAPK signaling pathways | Q35649728 |
| | Surveillance mechanism linking Bub1 loss to the p53 pathway | Q35850149 |
| | TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer | Q35906287 |
| | CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. | Q36103111 |
| | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. | Q36710840 |
| | Transcription regulation by mutant p53. | Q36777349 |
| | A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. | Q36908567 |
| | TTK/hMps1 mediates the p53-dependent postmitotic checkpoint by phosphorylating p53 at Thr18. | Q37192006 |
| | Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53. | Q37222088 |
| | Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets | Q37347297 |
| | Transcriptional control of the proliferation cluster by the tumor suppressor p53. | Q37660051 |
| | The p53 response element and transcriptional repression | Q37693593 |
| | p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment | Q37698274 |
| | Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements | Q37803147 |
| | Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1. | Q38319170 |
| | A novel Aurora-A-mediated phosphorylation of p53 inhibits its interaction with MDM2. | Q39234766 |
| | ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. | Q39337933 |
| | Targeting the mitotic checkpoint to kill tumor cells | Q39562014 |
| | Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. | Q39606792 |
| | Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability | Q39689315 |
| | Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation | Q39949011 |
| | Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy. | Q40009485 |
| | RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene | Q40252196 |
| | Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression | Q40263007 |
| | Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells | Q40266928 |
| | The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. | Q40275037 |
| | RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation | Q40344986 |
| | Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. | Q40568020 |
| | Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line. | Q41317071 |
| | Mitotic Kinases and p53 Signaling | Q42254103 |
| | Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis | Q44730805 |
| | SAPK pathways and p53 cooperatively regulate PLK4 activity and centrosome integrity under stress. | Q51011770 |
| P921 | main subject | computational biology | Q177005 |
| | RNA sequencing | Q2542347 |
| P304 | page(s) | 30 | |
| P577 | publication date | 2013-09-11 | |
| P1433 | published in | BMC Medical Genomics | Q15754662 |
| P1476 | title | Identification of potential synthetic lethal genes to p53 using a computational biology approach | |
| P478 | volume | 6 | |